该公司在一篇博客文章中详细阐述了这一流程。一家医疗保健公司周一宣布，已获得犹他州试点项目的授权，允许人工智能开具初步处方，包括痤疮治疗处方。
The company walked through the process in a blog post. A health care company announced Monday that it has received authorization for a pilot program in Utah allowing artificial intelligence to issue initial prescriptions, including acne treatment.
总部位于纽约市的 Nolla Health 在一篇介绍“人工智能驱动处方”的博客文章中推出了该项目，其痤疮治疗处方流程将分三个阶段逐步实施。
Nolla Health, which is based in New York City, introduced the program in a blog post announcing the "AI-powered prescriptions," its acne treatment prescription process, which will roll out in three stages.
该公司表示，这是美国首个获得州监管机构授权、允许人工智能开具初步处方的试点项目，并且是在与犹他州人工智能政策办公室合作后获批的。
The company said the pilot is the first in the U.S. authorized by a state regulator to allow AI to issue initial prescriptions, and that it was authorized after working with the Utah Office of Artificial Intelligence Policy.
该公司称，该项目旨在弥合医疗服务的“可及性差距”，具体而言，就是通过避免看皮肤科医生时所需的预约等待时间和相关费用。
The company says the program is designed to close "the access gap" to healthcare, in this case, by avoiding the appointment wait times and costs associated with visiting a dermatologist.
该公司表示，Nolla Derm 应用程序“每月仅需 4.99 美元即可开具有效的痤疮治疗处方”，并且“无需到诊所就诊”。博客文章指出，18 岁及以上的犹他州居民可以下载该应用程序，并以每月 4.99 美元的折扣价开始流程。
The company said the Nolla Derm application "will prescribe effective acne treatment from $4.99 a month" and require "no office visit." The post said Utah residents 18 and older can download the app and begin the process at a discounted rate of $4.99 per month.
在验证身份、提供知情同意并填写初步问卷后，患者需要进行“快速的五角度面部扫描”。文章称：“大约 10 到 15 分钟内，系统便会生成个性化的治疗方案，并在适当的情况下开具初步处方。”
After verifying their identity, providing informed consent and filling out an intake questionnaire, patients take a "quick five-angle face scan." "In about 10--15 minutes, this generates a personalized treatment plan and, if appropriate, an initial prescription," the post said.
根据该公司的说法，该试点项目将分三个阶段实施，每个阶段都有医生的参与。
The pilot will roll out in three stages with physician involvement in each, according to the company.
在第一阶段，涵盖首批100名患者，“两名持牌医生会独立审核并批准每一张由人工智能生成的处方，在处方送达患者之前完成这一流程。”
In the first stage, which includes the first 100 patients, "two licensed physicians independently review and approve every AI-generated prescription before it reaches the patient."
在第二阶段，将涵盖最多500名患者，“Nolla Derm将直接开具处方，医生会在事后对每例情况进行审核，审核频率至少为每周一次。”
In the second stage, which will include up to 500 patients, "Nolla Derm issues prescriptions directly, and a physician reviews every case after the fact, at least weekly."
在试点的第三阶段，每月将有10%的处方样本由医生进行审核。医生还将审核“所有涉及病情升级或出现副作用的案例”。该公司表示，第一阶段和第二阶段将持续至少四周和八周。
In the third stage of the pilot, a 10% sample of prescriptions each month will be reviewed by a physician. A physician will also review "every case involving an escalation or a side effect." The company said stages one and two would last at least four and eight weeks, respectively.
该帖子称：“进入下一阶段需要满足安全目标，包括与医生的意见一致率达到95%、未发生任何严重不良反应，并获得州政府的书面批准。”
"Moving to the next stage requires meeting safety targets, including 95% agreement with physicians and zero serious adverse events, and written approval from the state," the post said.
帖子还写道：“患者可以随时通过应用程序与持牌医生联系，无需支付额外费用。”
The post continued, "Patients can message a licensed physician through the app at any time, at no extra cost."
该公司表示，痤疮治疗是该技术可行的起点，因为这一领域“研究充分、风险较低，并有数十年的临床证据支持”。编者注：本文已进行更正，以明确Nolla Health总部位于纽约市。
The company said acne treatment was a viable starting point for the technology because it is "well understood, low risk, and backed by decades of clinical evidence." Editor's note: This story has been corrected to clarify that Nolla Health is based in New York City.